# OnCo record ret01 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ret01/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ret01" ;
  schema:name "ReT01 ACT"@en ;
  schema:alternateName "ReT01"@en, "Re-TIL"@en ;
  schema:description "ReT01 ACT is an experimental autologous tumour-infiltrating lymphocyte cell therapy from Beijing Xunsheng Biomedical Research, in phase 1 trials for advanced cervical cancer after failure of first-line systemic therapy and advanced solid tumours."@en ;
  schema:url <https://onco.cc/drugs/ret01/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <http://www.aeonvital.com/page141>, <http://www.aeonvital.com/page139>, <https://clinicaltrials.gov/study/NCT06257680>, <https://clinicaltrials.gov/search?intr=ReT01> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Autologous tumour-infiltrating lymphocyte (TIL) cell therapy" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:companies <https://onco.cc/companies/beijing-xunsheng-biomedical/> ;
  onco:trials <https://onco.cc/trials/nct06257680/> .